# KPL-387 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/kpl-387

> The next catalyst for KPL-387, sponsored by Kiniksa Pharmaceuticals International, plc (KNSA), is its topline data readout, Dec 2027 to Mar 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | KPL-387 |
| Codes | KPL-387 |
| Sponsor | Kiniksa Pharmaceuticals International, plc (KNSA) https://sec-api.dev/companies/knsa/catalysts |
| Indications | Pericarditis, [Recurrent Pericarditis](https://sec-api.dev/indications/recurrent-pericarditis) |
| Modality |  |
| FDA designations | orphan |

## Timeline

### Jun 2024: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-02-25, last confirmed 2026-02-24.
- SEC Form 10-K (accession 0001104659-26-019168): "In June 2024, we initiated a Phase 1 clinical trial of KPL-387 in healthy volunteers." https://www.sec.gov/Archives/edgar/data/1730430/000110465926019168/knsa-20251231x10k.htm
- SEC Form 10-Q (accession 0001104659-25-103180): "In June 2024, we initiated a Phase 1 clinical trial of KPL-387 in normal healthy volunteers." https://www.sec.gov/Archives/edgar/data/1730430/000110465925103180/knsa-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-009738): "In June 2024, we initiated a Phase 1 clinical trial of KPL-387 in normal healthy volunteers." https://www.sec.gov/Archives/edgar/data/1730430/000155837025009738/knsa-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-005847): "In June 2024, we initiated a Phase 1 clinical trial of KPL-387 in normal healthy volunteers." https://www.sec.gov/Archives/edgar/data/1730430/000155837025005847/knsa-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-001505): "In June 2024, we initiated a Phase 1 clinical trial of KPL-387 in normal healthy volunteers." https://www.sec.gov/Archives/edgar/data/1730430/000155837025001505/knsa-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-001505): "In June 2024, we initiated a Phase 1 clinical trial of KPL-387 in normal healthy volunteers and data from such study suggests that KPL-387 holds the potential for monthly subcutaneous dosing." https://www.sec.gov/Archives/edgar/data/1730430/000155837025001505/knsa-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-001505): "In June 2024, we initiated a Phase 1 clinical trial of KPL-387 in healthy volunteers." https://www.sec.gov/Archives/edgar/data/1730430/000155837025001505/knsa-20241231x10k.htm

### mid-2025: trial start

- Status: scheduled. Date confidence: half. Stage: 2/3.
- First seen 2025-02-25, last confirmed 2025-06-05.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-056665): "All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding: our plan to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025, with Phase 2 data expected in the second half of 2026, and that we remain on track to meeting such plan; our target profile of monthly dosing via a single subcutaneous injection in a liquid formulation for KPL-387; our belief that" https://www.sec.gov/Archives/edgar/data/1730430/000110465925056665/tm2517185d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-040641): "1 study support the development plan for KPL-387; Kiniksa plans to initiate a Phase 2/3 clinical trial in mid-2025." https://www.sec.gov/Archives/edgar/data/1730430/000110465925040641/tm2513395d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-016725): "We have interacted with the FDA and plan to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025." https://www.sec.gov/Archives/edgar/data/1730430/000110465925016725/tm257489d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-016725): "our plan to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025, with Phase 2 data expected in the second half of 2026" https://www.sec.gov/Archives/edgar/data/1730430/000110465925016725/tm257489d1_ex99-1.htm
- SEC Form 10-Q (accession 0001558370-25-005847): "In February 2025, we announced our plan to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025." https://www.sec.gov/Archives/edgar/data/1730430/000155837025005847/knsa-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-001505): "In February 2025, we announced our plan to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025." https://www.sec.gov/Archives/edgar/data/1730430/000155837025001505/knsa-20241231x10k.htm

### Jul 2025: trial start

- Status: completed. Date confidence: month. Stage: 2/3.
- First seen 2026-02-24, last confirmed 2026-02-24.
- SEC Form 10-K (accession 0001104659-26-019168): "In July 2025, we initiated our Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis, beginning with the Phase 2 dose-focusing portion of the study." https://www.sec.gov/Archives/edgar/data/1730430/000110465926019168/knsa-20251231x10k.htm

### late 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-07-29, last confirmed 2026-04-28.
- Press release filed with the SEC (EX-99) (accession 0001730430-26-000017): "our expectation to initiate the Phase 3 pivotal portion of the Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis by the end of 2026" https://www.sec.gov/Archives/edgar/data/1730430/000173043026000017/knsa-20260428xex99d1.htm
- SEC Form 10-Q (accession 0001104659-26-050359): "In April 2026, we announced our expectation to initiate a pivotal Phase 3 clinical trial of KPL-387 in recurrent pericarditis by the end of 2026." https://www.sec.gov/Archives/edgar/data/1730430/000110465926050359/knsa-20260331x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-071413): "our expectation to have data from the Phase 2 dose-focusing portion of our clinical trial of KPL-387 in recurrent pericarditis in the second half of 2026, and our plan to initiate the pivotal portion of the trial thereafter" https://www.sec.gov/Archives/edgar/data/1730430/000110465925071413/tm2521890d1_ex99-1.htm

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Pericarditis; Pericarditis Acute; Recurrent Pericarditis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07010159 (Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Kiniksa Pharmaceuticals International, plc." https://clinicaltrials.gov/study/NCT07010159

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Recurrent Pericarditis; Heart Diseases; Pericarditis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07288216 (Transition to KPL-387 Monotherapy Dosing & Administration Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Kiniksa Pharmaceuticals International, plc." https://clinicaltrials.gov/study/NCT07288216

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Pericarditis; Pericarditis Acute; Recurrent Pericarditis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07010159 (Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Kiniksa Pharmaceuticals International, plc." https://clinicaltrials.gov/study/NCT07010159

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Recurrent Pericarditis; Heart Diseases; Pericarditis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07288216 (Transition to KPL-387 Monotherapy Dosing & Administration Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Kiniksa Pharmaceuticals International, plc." https://clinicaltrials.gov/study/NCT07288216

## Same indication

- [CardiolRx™ (cardiolrx)](https://sec-api.dev/pdufa/cardiolrx) (CRDL)

Calendar months: [December 2027](https://sec-api.dev/fda-calendar/2027-12)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/kpl-387.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "KPL-387 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/kpl-387

```bibtex
@misc{secapidev_pdufa_kpl_387_20261116,
  title        = {KPL-387 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/kpl-387}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_kpl_387_20261116","title":"KPL-387 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/kpl-387","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
